WuXi AppTec Inc. today announced
that it has entered into a partnership with QIAGEN to provide an integrated
single solution for molecular biomarker development, validation and
personalized healthcare targets to their respective client bases. QIAGEN will
provide a complete portfolio of instrumentation, training, and consumables and
WuXi AppTec will provide laboratory facilities and staff to execute the
services. The laboratory will be located at WuXi AppTec's campus in Shanghai
and will begin operating immediately.
Under the terms of the partnership agreement, WuXi AppTec will also work
with QIAGEN to help develop biomarkers, assay panels, personalized healthcare
diagnostics, and other products that QIAGEN intends to bring to market. WuXi
AppTec will use QIAGEN's technologies for a broad range of applications in
support of drug discovery and development on behalf of the company's and
QIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other's
services to their respective customers. Both companies are working closely to
identify additional opportunities to deepen their relationship.
"WuXi AppTec has long been interested in partnering with a premier
international molecular biotechnology company like QIAGEN to support the
development of our biomarker business," said Dr. Ge Li, Chairman and CEO of
WuXi AppTec. "This partnership gives us access to innovative technologies and
processes that will allow us to better serve our customers."
"We are very pleased to have entered into this partnership with WuXi
AppTec, a global leader in providing integrated research and development
services to the pharmaceutical industry," said Dr. Victor Shi, President,
Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be
the first laboratory of its kind in Asia equipped with a standardized, fully
integrated, automated sample and assay technology platform for drug discovery
and development and molecular diagnostics in personalized healthcare and other
areas. We believe that this partnership is a significant milestone in
providing high-quality and complete automated solutions for the molecular
biomarker testing industry."
SOURCE WuXi AppTec Inc.